Chelsea Therapeutics is a biopharmaceutical company developing prescription products in multiple therapeutic categories such as RA, psoriasis and other inflammatory conditions.  These high-potential global opportunities are balanced by the development of the company’s orphan drug candidate Droxidopa, an oral therapeutic currently approved and marketed in Japan, for the treatment of neurogenic orthostatic hypotension. Chelsea is committed to creating value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline through acquisitions and alliances. » more

Neurogenic Orthostatic Hypotension
» visit the NOH Study Website to learn more
about our Phase III clinical trials in Neurogenic Orthostatic Hypotension